MOCHIDA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,110 JPY | +1.97% |
|
+2.47% | -4.89% |
| Apr. 25 | Hidehiro Imatsu named president of Goldman Sachs Japan | RE |
| Mar. 21 | Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 0.44 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm trades with high earnings multiples: 24.62 times its 2024 earnings per share.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.89% | 691M | - | ||
| +45.82% | 765B | C+ | ||
| -6.16% | 354B | C+ | ||
| +19.86% | 331B | B- | ||
| +9.32% | 299B | C+ | ||
| +18.86% | 248B | B+ | ||
| -1.92% | 219B | A+ | ||
| +11.05% | 216B | B- | ||
| +5.90% | 164B | C+ | ||
| -0.73% | 162B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4534 Stock
- Ratings Mochida Pharmaceutical Co., Ltd.
